Special Notice HEALTH AND HUMAN SERVICES, DEPARTMENT OF NATIONAL INSTITUTES OF HEALTH: Immunotox - Two 12-Month Extensions
The National Institute of Environmental Health Sciences (NIEHS) intends to extend Contract HHSN273201400017C with Burleson Research Technologies, Inc. on a sole-source basis. The purpose of this extension is to ensure the continuation of mission critical research while the NIEHS procurement team pursues the re-competition of these services under a new cost reimbursement contract. The contract will be extended for two 12-month options.
The Division of Translational Toxicology (DTT) uses in vitro and in vivo models to evaluate the effects of chemical, physical, and biological agents on the immune system. The objective of this R&D contract is to evaluate the complete scope of immunotoxicity, including measuring immune suppression or stimulation, evaluating allergic responses, and assessing the potential of a test agent to modulate immune function. Development and validation of new and improved methodology will also be required.
Burleson Research Technologies, Inc. is considered the only contractor that has a comprehensive understanding of the current technologies used at NIEHS and can meet the NIEHS and DTT’s needs during the two 12-month options. Awarding the contract to another source would result in substantial disruption, unnecessary costs, and unacceptable delays. By extending the contract with the incumbent contractor, the NIEHS can continue day-to-day operations and avoid disruptions to mission essential work.
The first option will be from August 13, 2024, through August 12, 2025, and the second option will be from August 13, 2025, through August 12, 2027. The contract value will increase accordingly.
Interested parties may submit a written capabilities statement if they believe they can fully meet the Government's requirement. The capabilities statement must be received by the response date listed in the posting. The Government will make a determination whether to compete the requirement based on the responses received.
For any questions regarding this notice, please contact Adam Muhsin at adam.muhsin@nih.gov.